Last Update: Jun 08, 2026
Post-marketing Database Study in Patients With Graft-Versus Host Disease for JAKAVI Tablets
ClinicalTrials.gov Identifier:
Novartis Reference Number:CINC424C1401
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Study Description
This study aims to evaluate the safety and effectiveness of Jakavi® (ruxolitinib) in patients with acute graft-versus host disease (GVHD) and chronic GVHD in clinical practice.
Graft-Versus-Host Disease
Recruiting
395
May 11, 2026
May 15, 2030
All
0 Years - (Child, Adult, Older Adult)
Eligibility Criteria
Inclusion Criteria:
* Patients with acute and chronic GVHD
* Patients treated with ruxolitinib
Exclusion Criteria:
None
Other protocol-defined inclusion/exclusion criteria may apply.
Novartis
Recruiting
Tokyo,105-6333,Japan
Worldwide Contacts
If the location of your choosing does not feature any contact detail, please reach out using the information below.